Prot#B3461045: A Phase 3 Multicenter, Open-Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg (or Tafamidis(06291826-00) 61 mg) in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)